• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 18, 2020 at 11:02: AM
via Mirati Therapeutics (NASDAQ:MRTX) has announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO) in patients with advanced or metastatic urothelial carcinoma. Data were presented at the European Society for Medical Oncology Virtual Congress.

article source
 

<



Similar threads

cafead
Mirati&#039;s Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
Replies
0
Views
130
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Mirati&#039;s flagship KRAS inhibitor Krazati gets rebuffed in Europe
Replies
0
Views
111
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Mirati&#039;s long wait for next lung cancer med ends in phase 3 failure
Replies
0
Views
329
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Mirati&#039;s KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Replies
0
Views
135
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field &#039;much...
Replies
0
Views
164
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote